Previous close | 0.0200 |
Open | 0.0100 |
Bid | 0.0000 |
Ask | 0.0700 |
Strike | 14.00 |
Expiry date | 2024-09-06 |
Day's range | 0.0100 - 0.0200 |
Contract range | N/A |
Volume | |
Open interest | 61 |
Claude Nicaise, M.D. appointed Chairman of the BoardAUSTIN, Texas, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced it has concluded its search for a Chief Executive Officer and that its Board of Directors has named Richard (Rick) Barry as CEO. Mr. Barry has served as a director of Cassava since June 2021. On July 17 of this year, the Board appointed him Executive Chairman of the Board and the Compan
AUSTIN, Texas, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it has been invited to present at the H.C. Wainwright 26th Annual Global Investment Conference, being held in New York. Rick Barry, Cassava’s Executive Chairman, will join in a ‘fireside chat’ with Vernon T. Bernardino, PhD., Managing Director, Biotechnology Equity Research, at H.C. Wainwright. Institutional investors
We recently compiled a list of the 7 Best Debt Free Stocks To Buy. In this article, we are going to take a look at where Cassava Sciences Inc (NASDAQ:SAVA) stands against the other debt free stocks. Debt has always been the fuel driving many companies in the equity markets. Access to cheap capital when […]